Rise and fall of BCR-ABL levels related to imatinib dosage.
 Marked variation in BCR-ABL levels was observed in patient A when the dosage was changed from 400 to 600 mg, whereas the changes were more subtle for patient B when the dosage was changed from 600 to 800 mg imatinib. Patient C had a confirmed loss of MMR more than 8 years after commencing 400 mg imatinib. The patient subsequently acknowledged that imatinib was ceased 6 weeks prior. All patients were followed in Adelaide.